Survival benefit for early hormone ablation in biochemically recurrent prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 2, 2007, Pages 101-109

  Tenenholz, Todd C ^a   Shields, Christian ^a   Ramesh, V Ramakrishnan ^b   Tercilla, Oscar ^a,c   Hagan, Michael P ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Androgen ablation; Biochemical recurrence; Prostate cancer; PSA

Indexed keywords

ANTIANDROGEN; DIETHYLSTILBESTROL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847360906     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.03.002     Document Type: Article

References (24)

1. Huggins C., and Hodges C.V. Studies on prostate cancer: I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 88 (2000) 3009-3014
3. Moul J.W. Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 21 (2003) 292-304
4. Johnstone P.A., Booth R., Riffenburgh R.H., et al. Initiation of salvage therapy for prostate cancer. Prostate Cancer Prostatic Dis 5 (2002) 136-143
5. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
6. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 79 (1997) 235-246
7. Scherr D., Swindle P.W., and Scardino P.T. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61 (2003) 14-24
8. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213-221
9. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
10. McCarthy J.F., Catalona W.J., and Hudson M.A. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol 151 (1994) 1575-1578
11. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
12. Lee W.R., Hanks G.E., and Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15 (1997) 230-238
13. Hanks G.E., D'Amico A., Epstein B.E., et al. Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 27 (1993) 125-127
14. DeWeese T.L., and Song D.Y. Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate. Urology 55 (2000) 169-174
15. Pollack A., and Zagars G.K. Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit?. Semin Radiat Oncol 8 (1998) 95-106
16. Litwin M.S. Quality of life following definitive therapy for localized prostate cancer: Potential impact of multiple therapies. Curr Opin Urol 13 (2003) 153-156
17. American Society for Therapeutic Radiation and Oncology (ASTRO). Consensus statement guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
18. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
19. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
20. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
21. Granfors T., Modig H., Damber J.E., et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 159 (1998) 2030-2034
22. Pollack A., Zagars G.K., and Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74 (1994) 670-678
23. Sylvester J., Grimm P., Blasco J., et al. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: A survey of practice patterns of urologists and radiation oncologists in the United States. Urology 58 (2001) 65-70
24. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141-1147